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Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance, obesity, and other features of metabolic syndrome. It is identified 
as the most common cause of liver enzyme derangement. Lately, NAFLD has generated interest in exploring treatment options, including weight 
loss and dietary interventions. An association of NAFLD with metabolic syndrome has been suggested in contemporary literature. In this study, 
we attempted to look into the association of NAFLD with metabolic syndrome. In this study, 80 adult NAFLD patients were recruited from a 
tertiary care hospital. Among these, 42 were males and 38 females with a mean age of 44.46±13.146 years (range 18–82 years). Grades of fatty 
liver and presence or absence of metabolic syndrome were studied in this patient population. Patients who did not qualify for the criteria of met-
abolic syndrome were placed in Group 1 and those who fulfilled the stated criteria were considered in Group 2. There were 29 (36.25%) patients 
in Group 1 and 51 (63.75%) in Group 2. All the patients in Group 1 were having Grade I fatty liver whereas patients in Group 2 were found to 
having varying grades of fatty liver, with six patients having Grade III fatty liver. We found statistically significant difference in various param-
eters of study (liver enzymes, high-density lipoprotein (HDL), triglycerides, and blood pressure) between Group 1 and Group 2. Ultrasound 
evidence of a fatty liver should be considered as a predictor of metabolic syndrome, and these patients must be investigated for the different 
components of metabolic syndrome so as to have early diagnosis and intervention to alter development of long-term metabolic disorders and 
their inherent complications.
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Introduction
Metabolic syndrome is a cluster of metabolic abnormalities. 
It helps detect people at risk of diabetes and cardiovascular 
disease. Nonalcoholic fatty liver disease (NAFLD) is defined 
as a disorder with excess fat in the liver due to nonalcoholic 
reasons. Glucose and triglycerides, which happen to be the 
two important components of metabolic syndrome, are over-
produced by fatty liver. Therefore, liver plays an important 
role in metabolic disorders. Prevalence of both metabolic syn-
drome and NAFLD increases with obesity. Other acquired 
causes for these disorders include excessive consumption 
of simple sugar and physical inactivity. NAFLD and meta-
bolic syndrome contribute to development of type  2 diabe-
tes, cardiovascular disease, and hepatocellular carcinoma. 
Metabolic syndrome has been defined in different ways and 
its association with NAFLD is increasingly studied world 
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over. It appears that NAFLD might turn out to be a predictor 
of development of these metabolic disorders  (1). The early 
detection of NAFLD helps clinicians take measures to avoid 
or delay the development of these metabolic disorders by uti-
lizing non-pharmacologic and pharmacologic measures. The 
National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III, 2001) guidelines for the diagnosis 
of metabolic syndrome require at least three of the following 
to label a patient with metabolic syndrome (2):
1. Central obesity: Waist circumference ≥102 cm or 40 
inches (males) and ≥88 cm or 36 inches (females).
2. Increase triglycerides ≥150 mg/dL. Reduce high-density 
lipoprotein (HDL) cholesterol (HDL-C), <40 mg/dL 
(males) and <50 mg/dL (females).
3. Blood pressure ≥130/85 mmHg.
4. Fasting plasma glucose ≥110 mg/dL.
There are hardly any studies which have investigated the con-
comitant occurrence of metabolic syndrome in asymptom-
atic patients with NAFLD (3,4). In a recent detailed review, 
various aspects of steatohepatitis and the factors contribut-
ing to it, including gene and environment interactions, have 
been elaborated (5).
Material and Methods
After having approval from Ethical Committee, we recruited 
80 adult patients who had been detected to have NAFLD 
(varying grades) based on ultrasonography (USG). These 
patients had no previous evidence of liver dysfunction. 
Patients who had a history of alcohol consumption of more 
than 20 g/day or who had a deranged liver functions in the 
past were not included in our study. Patients with hepatitis B 
surface antigen (HBsAg) and/or anti-hepatitis C virus (HCV) 
positive status, history of intake of drugs causing NAFLD, 
intake of lipid-lowering drugs, known patients of previous 
liver disease, and exposure to toxins or alternate medica-
tions were also excluded from our study. All participants 
were explained the purpose of this study and they provided 
informed consent. They were subjected to thorough check-up 
through history-taking, physical examination, blood pres-
sure, and body mass index (BMI) assessment. Liver function 
tests, lipid profile, fasting blood glucose, and postprandial 
blood glucose were carried out in all the included patients. 
Echogenicity of the liver was evaluated using Logiq 500 PRO 
series GE Doppler ultrasound machine with multifrequency 
curvilinear transducer having frequency of 3.5–5 MHz. Fatty 
liver was graded as follows:
• Mild (Grade I): Minimal diffused increase in hepatic echo-
genicity; normal visualization of intrahepatic vessel bor-
ders and diaphragm.
• Moderate (Grade II): Moderate diffused increase in 
hepatic echogenicity; slightly impaired visualization of 
intrahepatic vessels and diaphragm.
• Severe (Grade III): Marked increase in echogenicity; poor 
penetration of the posterior segment of right lobe of the 
liver and poor or non-visualization of hepatic vessels and 
diaphragm.
Patients with sonographic evidence of fatty liver along with 
levels of AST > 37 U/dL and ALT > 40 U/dL had their blood 
further investigated for serology for hepatitis B and hepatitis 
C virus. Waist circumference was measured as per NCEP 
ATP III guidelines (2). It was measured immediately above 
the iliac crest. BMI in the range of 18.5–24.9 kg/m2 was con-
sidered normal. BMI in the range of 25–29.9 kg/m2 was con-
sidered as overweight and BMI = 30 kg/m2 and above  was 
considered as obese. Metabolic syndrome was defined by 
using the ATP III proposal (2).
All the selected patients of this study were divided into the 
following two groups:
• Group 1: Patients with USG-documented fatty liver not 
fulfilling the criteria of metabolic syndrome.
• Group 2: Patients with USG-documented fatty liver and 
fulfilling the criteria of metabolic syndrome.
Results and Observations
This study included 80 patients: 42 males and 38 females with 
a mean age of 44.46±13.14 years (range 18–82 years). Clin-
ical and biochemical parameters of the patients are shown 
in Table 1. Group 1 had 29 and Group 2 had 51 patients. 
There was statistically significant difference in all the  studied 
parameters between the study groups, with patients in group 
2 having higher BMI, liver enzyme levels, systolic and dia-
stolic blood pressures. As can be seen in Table 2, higher the 
grade of fatty liver, more likely the patient had metabolic 
syndrome. Comparison of different BMI ranges between the 
two groups is shown in Table 3, indicating that more patients 
in Group 2 were overweight or obese.
Discussion
The histopatholigic profile of NAFLD ranges from sim-
ple steatosis to nonalcoholic steatohepatitis (NASH). Ini-
tially, it was considered as benign, but that is not the case 
now as more and more aspects of NAFLD are studied and 
information is accumulated. It contributes significantly to 
hepatic morbidity and mortality. Overtime, NAFLD may 
progress to cirrhosis, liver failure, and can lead to develop-
ment of hepatocellular carcinoma. Newer evidences sug-
gest its association with metabolic syndrome. NAFLD and 
metabolic syndrome share a common pathologic link called 
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Table 1: Mean values of variables used in the study.
Parameters Group N Mean Std. Deviation P-value
Age 1 29 35.31 10.146 <0.05
2 51 49.67 11.798
Total 80 44.46 13.146
AST 1 29 40.90 12.402 <0.05
2 51 60.88 18.265
Total 80 53.64 18.951
ALT 1 29 46.62 18.829 <0.05
2 51 69.67 17.303
Total 80 61.31 20.963
Body mass index (BMI) 1 29 24.88 1.967 <0.05
2 51 29.75 2.597
Total 80 27.99 3.346
Waist 1 29 89.90 6.635 <0.05
2 51 99.51 6.676
Total 80 96.03 8.090
Sr. TG 1 29 107.28 19.346 <0.05
2 51 160.22 36.532
Total 80 141.03 40.413
Sr. HDL 1 29 49.97 6.062 <0.05
2 51 40.45 6.564
Total 80 43.90 7.841
Blood glucose 1 29 82.21 7.575 <0.05
2 51 109.37 24.414
Total 80 99.53 23.880
BP (systoilc) 1 29 128.97 8.082 <0.05
2 51 146.90 8.857
Total 80 140.40 12.169
BP (diastolic) 1 29 83.52 6.063 <0.05
2 51 90.98 4.027
Total 80 88.28 6.027
AST: Aspartate aminotransferase; ALT :Alanine aminotransferase; TG: Triglyceride; BP: Blood Pressure; HDL: High density 
lipid; BMI: Body Mass Index
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insulin resistance. Kotronen et al. in their study observed 
that  content of liver fat was significantly increased in patients 
with metabolic syndrome as compared to those without syn-
drome, and this association was found to be independent of 
age, gender, and BMI (6). In the study conducted by Völzke 
et al., an association was established between hepatic steato-
sis, carotid atherosclerotic plaques, and endothelial dysfunc-
tion (7). India with a huge population base with changing 
lifestyles is encountering a marked rise in metabolic disor-
ders such as diabetes, metabolic syndrome, etc. There is a 
need of robust clinical studies so as to devise strategies to 
prevent the development of these disorders by addressing the 
risk factors and using largely non-pharmacologic measures 
to control the rise of these diseases. The relationship between 
NAFLD and metabolic syndrome has seldom been studied 
in the Indian context. The results of the study conducted by 
Marchesini et al. summarize the contemporary information 
on the observations that strongly suggest the association of 
NAFLD as a possible component of metabolic syndrome. It 
is observed that NAFLD is characterized by clinical and lab-
oratory data similar to those found in diabetes and obesity. 
NAFLD may be considered an additional feature of meta-
bolic syndrome, with specific hepatic insulin resistance (8). 
Younossi et al. in their study observed an association between 
NASH and metabolic disorders such as diabetes mellitus 
and obesity (9). The prevalence of NAFLD in the general 
population was 24.5% according to the results of a study 
conducted in India (10). Hanley et al. studied 633 subjects 
from the Insulin Resistance  Atherosclerosis Study (IRAS) 
who did not have  metabolic syndrome (11). The authors 
followed the subjects for 5.2 years. Assessment of aspartate 
aminotransferase (AST), alanine aminotransferase  (ALT), 
Table 2: Comparison of grades of fatty liver between the two groups.
Grades of Fatty Liver Total
I II III
Group 1 29 (55.8%)  0 (0%) 0 (0%) 29 (36.3%)
Group 2 23 (44.2%) 22 (100%) 6 (100%) 51 (63.8%)
Total 52 (100%) 22 (100%) 6 (100%) 80 (100%)
Table 3: Comparison of body mass index (BMI) values between the patients of two groups.
BMI (kg/m²) Group 1 Group 2 Total
Normal (18.5–24.9) 19 (65.5%) 0 (0%) 19 (23.8%)
Overweight (25–29.9) 10 (34.5%) 32 (62.7%) 42 (52.5%)
Obese  (>30) 0 (0%) 19 (37.3%) 19 (23.8%)
Total 29 (100%) 51 (100%) 80 (100%)
and C-reactive protein was done to find out whether liver 
enzymes could predict the development of metabolic syn-
drome (11). It was determined after 5.2 years of follow-up 
that 127 patients developed  metabolic syndrome and patients 
in the upper quartiles of ALT, AST, and C-reactive protein 
were at increased risk of having metabolic syndrome  (11). 
According to Wai-Sun et al., NAFLD has become a global 
epidemic, affecting 20–40% of the general adult popula-
tion  (12). In some patients, it leads a progressive course, 
resulting in cirrhosis, hepatocellular carcinoma, and liver- 
related mortality (12). NAFLD is observed in 10–24% of the 
general population in various countries (10,13). Marchesin 
et al. observed in their study that 80% of NAFLD patients 
were obese (8). In our study, only 23.8% of the patients had 
normal BMI, while 52.5% were overweight, 23.8% were 
obese, and 83.3% of the patients with Grade III fatty liver 
had low HDL  levels. Marshesini et al. reported in their study 
that type 2 diabetes mellitus was found in 33% of NAFLD 
patients (8). Another study conducted by Cortez et  al. 
in Japanese population demonstrated that prevalence of 
NAFLD was 43% in individuals with impaired fasting glu-
cose (14). Shannon et al. stated that the proportion of cases 
with hypertension was 21.2% greater in individuals having 
NAFLD than those without NAFLD (15). According to 
Yang et al., NAFLD was proposed to be an early predictor 
of metabolic dysfunction in healthy populations (16). Our 
study also established that blood pressure was higher in the 
group with metabolic syndrome compared to the group with-
out metabolic syndrome (P < 0.05). In a study conducted 
in the Indian context, 73% patients of metabolic syndrome 
according to NCEP ATP III criteria were having fatty liver 
compared to 38% in the control group (17).
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Conclusion
We directly compared NAFLD and metabolic syndrome 
according to NCEP ATP III criteria in normotensive and 
nondiabetic subjects, and found that metabolic syndrome 
was present in 63.7% of the study subjects. Therefore, we 
suggest that fatty liver, as analyzed by USG, could fairly pre-
dict the presence of metabolic syndrome.
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